MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Molecular Interventions 5:151-153, (2005)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.5.3.3
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kharasch, E. D.
Right arrow Articles by Watkins, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kharasch, E. D.
Right arrow Articles by Watkins, P. B.

Viewpoint

CYP3A Probes Can Quantitatively Predict the In Vivo Kinetics of Other CYP3A Substrates and Can Accurately Assess CYP3A Induction and Inhibition

Evan D. Kharasch1, Kenneth E. Thummel2 and Paul B. Watkins3

1 Assistant Dean for Clinical Research, Professor and Research Director, Department of Anesthesiology; Adjunct Professor of Medicinal Chemistry, University of Washington School of Medicine, Seattle, WA 98195;
2 Associate Dean for Research, Professor of Pharmaceutics, University of Washington School of Pharmacy, Seattle, WA 98195;
3 Director, General Clinical Research Center, Verne S. Caviness Distinguished Professor of Medicine, University of North Carolina, Chapel Hill, NC 27599

SUMMARY

Because the rates at which therapeutics are cleared from the body can affect their effectiveness, knowing and accounting for the variables that contribute to drug clearance is of utmost importance when designing a drug dosage regimen for patients. The activities of the manifold cytochrome P450 enzymes [(CYPs), the most clinically important of which is often CYP3A] must be considered as they are essential for modification and metabolism of compounds (i.e., therapeutic, xenobiotic, etc.) prior to their excretion. To this end, much research has been expended on trying to identify and develop drug probes that accurately predict the metabolism of CYP3A substrates in individuals. Recently, Benet has written on the futility of such an enterprise; however, other researchers believe the identification of valuable predictive probes is not only possible but crucial.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.